The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory

Journal of Cellular Biochemistry

Volumn 112, Issue 9, 2011, Pages 2222-2229

  Rajamannan, Nalini M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Lipids; Lrp5; Osteoblastogenesis; Wnt

Indexed keywords

LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; WNT PROTEIN;

ARTICLE; ATHEROSCLEROSIS; BONE; CELL GROWTH; ENDOTHELIUM CELL; HEART; LIPOPROTEIN METABOLISM; OSTEOBLAST; OSTEOBLASTOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VALVULAR HEART DISEASE;

ANIMALS; ATHEROSCLEROSIS; HEART VALVE DISEASES; HEART VALVES; HEMODYNAMICS; HUMANS; LIPOPROTEINS, LDL; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; OSTEOGENESIS; RISK FACTORS; WNT SIGNALING PATHWAY;

EID: 84860390043     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23182     Document Type: Article

References (68)

1. Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, Haynatzki GR, Babij P, Allen KM, Yaworsky PJ, Bex F, Recker RR,. 2004. Bone biomechanical properties in LRP5 mutant mice. Bone 35: 162-169. (Pubitemid 38789159)
2. Alfieri CM, Cheek J, Chakraborty S, Yutzey KE,. 2010. Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol 338: 127-135.
3. Aronow WS, Schwartz KS, Koenigsberg M,. 1987. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 59: 998-999. (Pubitemid 17074253)
4. Aronow WS, Ahn C, Kronzon I,. 2001a. Association of mitral annular calcium with symptomatic peripheral arterial disease in older persons. Am J Cardiol 88: 333-334. (Pubitemid 32721972)
5. Aronow WS, Ahn C, Kronzon I, Goldman ME,. 2001b. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88: 693-695. (Pubitemid 32831111)
6. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F,. 2003. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18: 960-974. (Pubitemid 37294932)
7. Bernoulli D,. 1738. Hydrodynamica sive de viribus et motibus fluidorum commentarrii. Strasbourg: Argentoratum. St31.
8. Boon A, Cheriex E, Lodder J, Kessels F,. 1997. Cardiac valve calcification: Characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 78: 472-474. (Pubitemid 27515107)
9. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP,. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513-1521. (Pubitemid 34755690)
10. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault M, Couet J, Pibarot P,. 2006. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 47: 2229-2236. (Pubitemid 43795081)
11. Brown SD, Twells RC, Hey PJ, Cox RD, Levy ER, Soderman AR, Metzker ML, Caskey CT, Todd JA, Hess JF,. 1998. Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun 248: 879-888. (Pubitemid 28404516)
12. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM,. 2006. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47: 1707-1712.
13. Chan KL, Ghani M, Woodend K, Burwash IG,. 2001. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol 88: 690-693. (Pubitemid 32831110)
14. Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA,. 2001. Association between calcific aortic stenosis and hypercholesterolemia: Is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol 24: 52-55. (Pubitemid 32044545)
15. Deutscher S, Rockette HE, Krishnaswami V,. 1984. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis 37: 407-415. (Pubitemid 14134891)
16. Dong Y, Lathrop W, Weaver D, Qiu Q, Cini J, Bertolini D, Chen D,. 1998. Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. Biochem Biophys Res Commun 251: 784-790. (Pubitemid 28512788)
17. Faggiano P, Antonini-Canterin F, Baldessin F, Lorusso R, D'Aloia A, Cas LD,. 2006. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound 4: 27.
18. Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S, Kim DH, Ioka RX, Ono M, Tomoyori H, Okubo M, Murase T, Kamataki A, Yamamoto J, Magoori K, Takahashi S, Miyamoto Y, Oishi H, Nose M, Okazaki M, Usui S, Imaizumi K, Yanagisawa M, Sakai J, Yamamoto TT,. 2003. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA 100: 229-234. (Pubitemid 36078057)
19. Gessert S, Kuhl M,. The multiple phases and faces of wnt signaling during cardiac differentiation and development. Circ Res 107: 186-199.
20. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, Osteoporosis-Pseudoglioma Syndrome Collaborative G. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523. (Pubitemid 33152786)
21. Grande-Allen KJ, Calabro A, Gupta V, Wight TN, Hascall VC, Vesely I,. 2004. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: Association with regions of tensile and compressive loading. Glycobiology 14: 621-633. (Pubitemid 38923644)
22. Grande-Allen KJ, Borowski AG, Troughton RW, Houghtaling PL, Dipaola NR, Moravec CS, Vesely I, Griffin BP,. 2005. Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: An extracellular matrix and echocardiographic study [see comment]. J Am Coll Cardiol 45: 54-61. (Pubitemid 40052025)
23. Hassler C, Cruciat CM, Huang YL, Kuriyama S, Mayor R, Niehrs C,. 2007. Kremen is required for neural crest induction in Xenopus and promotes LRP6-mediated Wnt signaling. Development 134: 4255-4263.
24. Hatle L, Angelsen BA, Tromsdal A,. 1980. Non-invasive assessment of aortic stenosis by Doppler ultrasound. Br Heart J 43: 284-292. (Pubitemid 10096613)
25. Hey PJ, Twells RC, Phillips MS, Yusuke N, Brown SD, Kawaguchi Y, Cox R, Guochun X, Dugan V, Hammond H, Metzker ML, Todd JA, Hess JF,. 1998. Cloning of a novel member of the low-density lipoprotein receptor family. Gene 216: 103-111. (Pubitemid 28389107)
26. Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L,. 1985. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol 55: 744-747. (Pubitemid 15148253)
27. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO,. 2004. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19: 2033-2040. (Pubitemid 41103418)
28. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK,. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 93: 1885-1893. (Pubitemid 24143065)
29. Jian B, Jones PL, Li Q, Mohler ER III, Schoen FJ, Levy RJ,. 2001. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159: 321-327. (Pubitemid 33704217)
30. Johnson ML, Summerfield DT,. 2005. Parameters of LRP5 from a structural and molecular perspective. Crit Rev Eukaryot Gene Expr 15: 229-242.
31. Johnson ML, Harnish K, Nusse R, Van Hul W,. 2004. LRP5 and Wnt signaling: A union made for bone. J Bone Miner Res 19: 1749-1757. (Pubitemid 41103424)
32. Kim DH, Inagaki Y, Suzuki T, Ioka RX, Yoshioka SZ, Magoori K, Kang MJ, Cho Y, Nakano AZ, Liu Q, Fujino T, Suzuki H, Sasano H, Yamamoto TT,. 1998. A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J Biochem 124: 1072-1076. (Pubitemid 29017294)
33. Komekado H, Yamamoto H, Chiba T, Kikuchi A,. 2007. Glycosylation and palmitoylation of Wnt-3a are coupled to produce an active form of Wnt-3a. Genes Cells 12: 521-534. (Pubitemid 46488587)
34. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis R,. 1994. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 15: 865-870. (Pubitemid 24223943)
35. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML,. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70: 11-19. (Pubitemid 34031693)
36. Liu W, Mani S, Davis NR, Sarrafzadegan N, Kavathas PB, Mani A,. 2008. Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ Res 103: 1280-1288.
37. Magoori K, Kang MJ, Ito MR, Kakuuchi H, Ioka RX, Kamataki A, Kim DH, Asaba H, Iwasaki S, Takei YA, Sasaki M, Usui S, Okazaki M, Takahashi S, Ono M, Nose M, Sakai J, Fujino T, Yamamoto TT,. 2003. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 278: 11331-11336. (Pubitemid 36792690)
38. Makkena B, Salti H, Subramaniam M, Thennapan S, Bonow RH, Caira F, Bonow RO, Spelsberg TC, Rajamannan NM,. 2005. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol 45: 631-633. (Pubitemid 40222262)
39. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP,. 2007. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315: 1278-1282. (Pubitemid 46364265)
40. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF,. 1991. Development and progression of aortic valve stenosis: Atherosclerosis risk factors-A causal relationship? A clinical morphologic study. Clin Cardiol 14: 995-999.
41. Mohler ER III, Adam LP, McClelland P, Graham L, Hathaway DR,. 1997. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 17: 547-552. (Pubitemid 27133146)
42. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS,. 2001. Bone formation and inflammation in cardiac valves. Circulation 103: 1522-1528. (Pubitemid 32226259)
43. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, Otto CM,. 1995a. Osteopontin is expressed in human aortic valvular lesions. Circulation 92: 2163-2168.
44. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, Otto CM,. 1995b. Osteopontin is expressed in human aortic valvular lesions [comment]. Circulation 92: 2163-2168.
45. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS,. 1999. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly [comment]. N Engl J Med 341: 142-147. (Pubitemid 29325741)
46. Palta S, Pai AM, Gill KS, Pai RG,. 2000. New insights into the progression of aortic stenosis: Implications for secondary prevention. Circulation 101: 2497-2502. (Pubitemid 30366254)
47. Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM,. 2003. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 91: 97-99. (Pubitemid 36050783)
48. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC,. 2000. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407: 535-538.
49. Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S,. 2001. Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104: 1927-1932. (Pubitemid 32983236)
50. Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli LG, Edwards WD, Tajik AJ, Schwartz RS,. 2001. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 10: 371-374. (Pubitemid 32454760)
51. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC,. 2002. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105: 2260-2265.
52. Rajamannan NM, Edwards WD, Spelsberg TC,. 2003a. Hypercholesterolemic aortic-valve disease. N Engl J Med 349: 717-718.
53. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T,. 2003b. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107: 2181-2184. (Pubitemid 36547209)
54. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T,. 2003c. Human aortic valve calcification is associated with an osteoblast phenotype [see comment]. Circulation 107: 2181-2184. (Pubitemid 36547209)
55. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC,. 2005a. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112: I229-I234. (Pubitemid 41266679)
56. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC,. 2005b. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 91: 806-810. (Pubitemid 40769233)
57. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H,. 2000. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343: 611-617. (Pubitemid 30659472)
58. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA,. 2005. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115: 1210-1220. (Pubitemid 40629039)
59. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM,. 1997. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29: 630-634. (Pubitemid 27116107)
60. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, He X,. 2004. A mechanism for Wnt coreceptor activation. Mol Cell 13: 149-156. (Pubitemid 38117123)
61. Tomaszewski M, Charchar FJ, Barnes T, Gawron-Kiszka M, Sedkowska A, Podolecka E, Kowalczyk J, Rathbone W, Kalarus Z, Grzeszczak W, Goodall AH, Samani NJ, Zukowska-Szczechowska E,. 2009. A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler Thromb Vasc Biol 29: 1316-1321.
62. Westendorf JJ, Kahler RA, Schroeder TM,. 2004. Wnt signaling in osteoblasts and bone diseases. Gene 341: 19-39. (Pubitemid 39335880)
63. Whittaker P, Boughner DR, Perkins DG, Canham PB,. 1987. Quantitative structural analysis of collagen in chordae tendineae and its relation to floppy mitral valves and proteoglycan infiltration. Br Heart J 57: 264-269. (Pubitemid 17039354)
64. Williams BO, Insogna KL,. 2009. Where Wnts went: The exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res 24: 171-178.
65. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR,. 1997. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 78: 475-479. (Pubitemid 27515108)
66. Wooley CF, Baker PB, Kolibash AJ, Kilman JW, Sparks EA, Boudoulas H,. 1991. The floppy, myxomatous mitral valve, mitral valve prolapse, and mitral regurgitation. Prog Cardiovasc Dis 33: 397-433.
67. Yamamoto H, Komekado H, Kikuchi A,. 2006. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 11: 213-223. (Pubitemid 44138502)
68. Zylstra CR, Wan C, VanKoevering KK, Sanders AK, Lindvall C, Clemens TL, Williams BO,. 2008. Gene targeting approaches in mice: Assessing the roles of LRP5 and LRP6 in osteoblasts. J Musculoskelet Neuronal Interact 8: 291-293.